adagrasib

AXP000024.1 · Targeted small molecule

Platform
small molecule
Targets
KRAS
Originator
Mirati Therapeutics
Sponsor
Bristol Myers Squibb

Names

NameTypeSource
adagrasibpreferred name, INNcurator, ncit
Krazatibrandfda
MRTX849codencit

Cross-references

NCI Thesaurus
C157493
Wikidata
Q105816120
FDA UNII
8EOO6HQF8Y

Approvals

No regulatory approval recorded.

Clinical trials (39)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT07543172CIMAvax-EGF With KRAS G12C Inhibitor for the Treatment of Advanced, KRAS G12C Mutated Non Small Cell Lung CancerNot yet recruitingPhase 22026-10-152029-06-0129Advanced Lung Non-Small Cell Carcinoma; Stage III Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8
NCT07723118A Study to Assess the Pharmacokinetics, Safety and Tolerability of Single-dose Adagrasib (BMS-986503) in Healthy Participants of Japanese DescentCompletedPhase 12026-08-052026-09-0810Healthy Participants
NCT07382726Phase 1 Study Of Izalontamab Brengitecan + Adagrasib In NSCLC - The IZA-A TrialRecruitingPhase 12026-05-152027-12-2418Non-small Cell Lung Cancer
NCT07415031A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib StudiesRecruitingPhase 22026-05-062028-02-16170Solid Tumors
NCT07288034Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP TrialRecruitingPhase 22026-05-012028-10-08535Lung Non-Small Cell Carcinoma; Stage IIIB Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8
NCT07318389ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal CancerRecruitingEarly phase 12026-04-222027-11-14100Dynamic Tumor Resistance; Metastatic Colorectal Cancer
NCT06875310A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)RecruitingPhase 32025-04-242029-09-07630Carcinoma, Non-Small-Cell Lung
NCT06764771A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant TumorsRecruitingPhase 12025-03-252027-10-15437Advanced Malignant Tumors
NCT06801418Bioequivalence Study Between Adagrasib Reference Tablets and High Drug Load TabletsCompletedPhase 12025-02-042025-06-19160Healthy Volunteers
NCT06497556A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung CancerActive not recruitingPhase 32024-09-232026-05-19338KRAS G12C Lung Cancer; Non-Small Cell Lung Cancer
NCT06412198A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C MutationsRecruitingPhase 1/22024-08-282029-03-0131KRAS G12C Mutations; Metastatic Colorectal Cancer
NCT06248606Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain MetastasesRecruitingPhase 22024-08-062027-02-2530KRAS G12C; NSCLC; Non Small Cell Lung Cancer
NCT05853575Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)Active not recruitingPhase 22024-02-012026-10-30200Advanced Cancer; Malignant Neoplasm of Lung; Metastatic Cancer
NCT06130254Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung CancersTerminatedPhase 12024-01-302024-06-141Advanced Solid Tumor; Non-small Cell Lung Cancers
NCT06039384A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C MutationTerminatedPhase 12023-12-282025-04-116Advanced Solid Tumors
NCT05722327Phase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal CancerActive not recruitingPhase 12023-12-062027-09-3024Colon Cancer; Colorectal Cancer
NCT06024174A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid TumorsTerminatedPhase 1/22023-11-092024-05-135Advanced Solid Tumors
NCT06026410KO-2806 Monotherapy and Combination Therapies in Advanced Solid TumorsRecruitingPhase 12023-10-182027-01300Clear Cell Renal Cell Carcinoma (ccRCC); Colorectal Cancer (CRC); Non Clear Cell Renal Cell Carcinoma (nccRCC); Non Small Cell Lung Cancer (NSCLC); Pancreatic Ductal Adenocarcinoma (PDAC); Renal Cell Carcinoma (Kidney Cancer); Solid Tumors With HRAS Alterations
NCT05840510Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer With a KRAS G12C Mutation (KRYSTAL -19)TerminatedPhase 12023-08-072024-12-276Advanced Cancer; Malignant Neoplastic Disease; Metastatic Cancer; NSCLC; Solid Tumor, Adult
NCT05924152A PK Study to Assess the Drug-drug Interaction of a BCRP Inhibitor on AdagrasibCompletedPhase 12023-06-292023-08-0916Healthy Adults
NCT05673187Adagrasib in Patients With KRASG12C-mutant NSCLC Who Are Elderly or Have Poor Performance StatusActive not recruitingPhase 22023-06-122025-07-2868KRAS P.G12C; NSCLC Stage IV
NCT05868356A PK Study to Assess the Drug-drug Interaction of a Strong CYP2C8 Inhibitor on AdagrasibCompletedPhase 12023-06-012023-07-2518Healthy Adults
NCT05634525Phase Ib Trial of the KRASG12C Inhibitor Adagrasib (MRTX849) in KRAS G12C Mutant Metastatic Pancreatic Cancer PatientsWithdrawnPhase 12023-05-032025-07-210Metastatic Pancreatic Cancer
NCT05848843A Phase I Study of Adagrasib and Durvalumab for Treatment of Advanced Non-small Cell Lung Cancers and Gastro-intestinal Cancers Harboring KRAS G12C MutationsWithdrawnPhase 12023-04-252024-01-160Gastro-intestinal Cancer; Lung Cancer
NCT05472623Neoadjuvant KRAS G12C Directed Therapy With Adagrasib (MRTX849) With or Without NivolumabWithdrawnPhase 22023-03-212025-06-010Resectable Non-Small Cell Lung Cancer
NCT05578092A Phase 1 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK PathwayTerminatedPhase 12022-12-022026-02-0364Advanced Solid Tumor; Colo-rectal Cancer; Non Small Cell Lung Cancer; Solid Tumor
NCT05609578Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C MutationActive not recruitingPhase 22022-11-222026-09-3090Advanced NSCLC; Metastatic Lung Cancer
NCT05375994Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC PatientsCompletedPhase 1/22022-08-012026-06-1512Advanced Cancer; KRAS Activating Mutation; Malignant Neoplasm of Lung; Malignant Neoplastic Disease; Metastatic Cancer; Non Small Cell Lung Cancer
NCT05263986The Clinical Trial to Evaluate the Pharmacokinetics and Safety of MRTX849 in Patients With Advanced Solid TumorsUnknownPhase 12022-05-302023-10-3122Advanced or Metastatic Solid Tumor
NCT05178888Adagrasib in Combination With Palbociclib in Patients With Advanced Solid Tumors (KRYSTAL-16)CompletedPhase 12022-01-202023-06-1511Advanced Solid Tumor
NCT04975256Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)TerminatedPhase 12021-07-282022-11-027Advanced Cancer; Malignant Neoplasm of Colon; Malignant Neoplasm of Lung; Malignant Neoplastic Disease; Metastatic Cancer
NCT04793958Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)Active not recruitingPhase 32021-06-242026-01-16461Advanced Colorectal Cancer; Metastatic Colorectal Cancer
NCT04685135Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C MutationActive not recruitingPhase 32021-02-232023-12-30453Advanced Non Small Cell Lung Cancer; Metastatic Non Small Cell Lung Cancer
NCT04613596Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7RecruitingPhase 2/32020-12-022028-10-31626Advanced Non-Small Cell Lung Cancer; Metastatic Non-Small Cell Lung Cancer
NCT04418661Safety and Efficacy Study of Vociprotafib (SAR442720) in Combination With Other Agents in Advanced MalignanciesTerminatedPhase 1/22020-06-092024-04-0465Metastatic Neoplasm
NCT04330664Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)CompletedPhase 12020-04-072022-07-2986Advanced Cancer; Malignant Neoplastic Disease; Metastatic Cancer
NCT03994796Genetic Testing in Guiding Treatment for Patients With Brain MetastasesActive not recruitingPhase 22019-10-172025-11-1350CDK Gene Mutation; KRAS G12C Mutation; Metastatic Malignant Neoplasm in the Brain; Metastatic Malignant Solid Neoplasm; NTRK Family Gene Mutation; PI3K Gene Mutation; ROS1 Gene Mutation
NCT03785249Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1Active not recruitingPhase 1/22019-01-152026-06-23731Advanced Cancer; Malignant Neoplastic Disease; Metastatic Cancer
NCT05162443Expanded Access of Adagrasib (MRTX849) in Patients With Advanced Solid Tumors Who Have a KRAS G12C MutationApproved for marketingAdvanced Cancer; Malignant Neoplasm; Metastatic Cancer

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 41907597Case Report: From metabolic normalization to incidental type A aortic dissection in immune checkpoint inhibitor-associated aortitis.Frontiers in oncology2026name in abstract: adagrasib
PMID 42405535Durable response to sotorasib in KRAS G12C-mutant intrahepatic cholangiocarcinoma: a case report.The oncologist2026name in abstract: adagrasib
PMID 42528143ctDNA Detection of Polyclonal KRAS Resistance in Adagrasib-Treated NSCLC.Thoracic cancer2026name in title: adagrasib
PMID 42745627Plain language summary of the KRYSTAL-12 study results: adagrasib for non-small cell lung cancer with KRASG12C mutations.Future oncology (London, England)2026cited by trial NCT04685135
PMID 42929675Divarasib as Compared with Sotorasib or Adagrasib in KRAS G12C-Mutated NSCLC.The New England journal of medicine2026cited by trial NCT06497556
PMID 39752885Development of KRAS Inhibitors and Their Role for Metastatic Colorectal Cancer.Journal of the National Comprehensive Cancer Network : JNCCN2025cited by trial NCT04793958
PMID 40542959Matching-Adjusted Indirect Comparison of Sotorasib Versus Adagrasib in Previously Treated Advanced/Metastatic Non-Small Cell Lung Cancer Harboring KRAS G12C Mutation.Advances in therapy2025name in title: adagrasib
PMID 40783289Adagrasib versus docetaxel in KRASG12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial.Lancet (London, England)2025cited by trial NCT04685135
PMID 41029058Real-world adverse event analysis of Adagrasib: Insights from the FAERS database.Medicine2025name in title: adagrasib
PMID 41355935Unlocking New Treatment Possibilities for Metastatic Endometrial Cancer With KRAS G12C Mutation.Case reports in oncological medicine2025name in abstract: adagrasib
PMID 38451823Twelve-month progression-free survival with sotorasib and panitumumab in KRAS G12C mutant metastatic colorectal cancer.Anti-cancer drugs2024name in abstract: adagrasib
PMID 38550295Prolonged Cancer Control With Adagrasib in Patients With Metastatic, KRASG12C-Mutated NSCLC After Sotorasib-Induced Hepatotoxicity: A Case Report.JTO clinical and research reports2024name in title: adagrasib
PMID 38579193Adagrasib Treatment After Sotorasib-Related Hepatotoxicity in Patients With KRASG12C-Mutated Non-Small Cell Lung Cancer: A Case Series and Literature Review.JCO precision oncology2024cited by trial NCT05472623
PMID 38587856Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer.Cancer discovery2024name in title: adagrasib
PMID 38996797Oral ADAGRASIB associated with cetuximab unblocks obstructed colorectal cancer.European journal of cancer (Oxford, England : 1990)2024name in title: adagrasib
PMID 39534868Polyradiculitis as a Neurological Complication Associated with Adagrasib: A Case Report.Case reports in oncology2024name in title: adagrasib
PMID 36546659Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C.The New England journal of medicine2023cited by trial NCT03785249
PMID 37099736Adagrasib in Advanced Solid Tumors Harboring a KRASG12C Mutation.Journal of clinical oncology : official journal of the American Society of Clinical Oncology2023cited by trial NCT03785249
PMID 37327468Intracranial Efficacy of Adagrasib in Patients From the KRYSTAL-1 Trial With KRASG12C-Mutated Non-Small-Cell Lung Cancer Who Have Untreated CNS Metastases.Journal of clinical oncology : official journal of the American Society of Clinical Oncology2023cited by trial NCT03785249
PMID 35167329First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRASG12C Solid Tumors (KRYSTAL-1).Journal of clinical oncology : official journal of the American Society of Clinical Oncology2022cited by trial NCT03785249
PMID 35404402Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRASG12C-Mutant Non-Small Cell Lung Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research2022cited by trial NCT03785249
PMID 35658005Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation.The New England journal of medicine2022cited by trial NCT03785249
PMID 35666594Adagrasib Response Remains Strong in NSCLC.Cancer discovery2022name in title: adagrasib
PMID 36353445Molecular docking analysis reveals differential binding affinities of multiple classes of selective inhibitors towards cancer-associated KRAS mutants.3 Biotech2022name in abstract: adagrasib
PMID 34161704Acquired Resistance to KRASG12C Inhibition in Cancer.The New England journal of medicine2021cited by trial NCT03785249
PMID 31658955The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.Cancer discovery2020name in title: MRTX849
PMID 32479604Receptor discordance in breast cancer brain metastases: when knowledge is power.Neuro-oncology2020cited by trial NCT03994796

Other papers

Preclinical studies, reviews and other papers that name it, newest 100 shown.

PubMedTitleJournalYearLinked by
PMID 40011229Post-marketing safety of Adagrasib: a disproportionality analysis based on the FAERS database.Expert opinion on drug safety2026name in title: adagrasib
PMID 40844328Clinical Outcomes and Safety Profile of Adagrasib in KRAS G12C-Mutated Solid Tumors: A Single-Arm Meta-Analysis.American journal of clinical oncology2026name in title: adagrasib
PMID 40991960Optimizing KRAS Therapeutics for Non-Small Cell Lung Cancer.Annual review of medicine2026name in abstract: adagrasib
PMID 41191614A novel anticancer natural product SP09 selectively targets KRAS-mutant NSCLC through LKB1/AMPK/mTOR modulation: implications for novel therapeutic development.Anti-cancer drugs2026name in abstract: adagrasib
PMID 41340466Activity of Direct KRAS(G12C) Inhibitors in Preclinical Models of Pediatric Cancer.Molecular cancer therapeutics2026name in abstract: adagrasib
PMID 41453423Micellar co-delivery of KRAS-mutant inhibitors and TLR7/8 agonists synergizes targeted therapy and immunotherapy in lung cancer.Acta biomaterialia2026name in abstract: adagrasib
PMID 41506251In-Source Fragmentation of Pyrrolidine-Containing KRAS Scaffolds Leads to Enhanced Structure Elucidation and Tandem Mass Spectral Quality.Journal of the American Society for Mass Spectrometry2026name in abstract: adagrasib
PMID 41508946Advances in targeting KRAS mutations: A promising approach for the treatment of non‑small cell lung cancer (Review).Oncology reports2026name in abstract: adagrasib
PMID 41529383Advances on drug therapy for KRASG12C-mutant non-small-cell lung cancer.Translational oncology2026name in abstract: adagrasib
PMID 41563236From class effects to specificity FAERS evidence and network mapping of adverse events in NSCLC targeted therapy.International journal of surgery (London, England)2026name in abstract: adagrasib
PMID 41581311Targeting HGF/MET and CXCL1/CXCR2 axes bypasses resistance to KRASG12C inhibitors in NSCLC.Lung cancer (Amsterdam, Netherlands)2026name in abstract: adagrasib
PMID 41592443The Gaussian network model as a framework for allosteric analysis: dynamic distance, edge centrality, and entropy sensitivity in KRAS.Physical biology2026name in abstract: adagrasib
PMID 41633936Design and Synthesis of KRASG12C Inhibitors for Antitumor Evaluation Harboring Combination Therapy with Nrf2, PARP-7, and Pan-USP Inhibitors to Alleviate Drug Resistance Synergistically.Journal of medicinal chemistry2026name in abstract: MRTX849
PMID 41654096Real-world evidence for 10 oncology drugs approved in the last 5 years: A comprehensive narrative synthesis.Critical reviews in oncology/hematology2026name in abstract: adagrasib
PMID 41663526Therapeutic advances with KRASG12C inhibitors and combination strategies in non-small cell lung cancer brain metastases.Cancer gene therapy2026name in abstract: adagrasib
PMID 41670818Genomic alterations and their correlation with metabolic-related genes in lung cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026name in abstract: adagrasib
PMID 41697749Cotargeting DNA topoisomerase II enhances efficacy of RAS-targeted therapy in KRAS-mutant cancer models.The Journal of clinical investigation2026name in abstract: adagrasib
PMID 41697929KRAS Inhibition in Non-Small Cell Lung Cancer with Central Nervous System Involvement: Current Evidence and Future Directions.Oncology research and treatment2026name in abstract: adagrasib
PMID 41715254The polyamine inhibitor SAM486A increases the efficacy of adagrasib in non-small cell lung cancer cells harboring KRASG12C mutation.Biological research2026name in title: adagrasib
PMID 41784211A Systematic Review of the Efficacy of KRAS p.G12C Inhibitors in Metastatic Colorectal Cancer: The Current State of Science.Cancer investigation2026name in abstract: adagrasib
PMID 41822354Tumor microenvironment-activated ferritin nanovector enables enhanced tumor delivery of KRASG12C inhibitors and degraders.Frontiers in cell and developmental biology2026name in abstract: adagrasib
PMID 41830517MRTX1133 suppresses ERK signaling but elicits context-dependent antiproliferative responses in KRAS (G12C) cancer cells.Molecular cancer therapeutics2026name in abstract: adagrasib
PMID 41888140Small-molecule degraders for oncogenic KRASG12C and pan-KRAS mutations.Nature communications2026name in abstract: MRTX849
PMID 41898563MicroRNA Mimics Based on the miR-15/107 Consensus Sequence Sensitise NSCLC Cells to Targeted Therapy.International journal of molecular sciences2026name in abstract: adagrasib
PMID 41998662MXD4 enhances resistance to KRAS G12C-targeted therapy in lung adenocarcinoma by suppressing ACSL4-mediated ferroptosis.Respiratory research2026name in abstract: adagrasib
PMID 42003513Combining cutting edge computational and experimental methods for targeting KRAS mutations in non-small cell lung cancer.Expert opinion on drug discovery2026name in abstract: adagrasib
PMID 42030031GAP mimetic activity of pan-Ras TCI daraxonrasib synergizes with K-Ras Switch-II pocket inhibition.Biological chemistry2026name in abstract: adagrasib
PMID 42031346From G12C To pan-RAS: The expanding therapeutic landscape of KRAS-mutant NSCLC.Critical reviews in oncology/hematology2026name in abstract: adagrasib
PMID 42041157MRTX1133 Suppresses ERK Signaling but Elicits Context-Dependent Antiproliferative Responses in KRAS (G12C) Cancer Cells.Molecular cancer therapeutics2026name in abstract: adagrasib
PMID 42055521KRAS G12C inhibitor outcomes in advanced non-small cell lung cancer by smoking history, performance status, and KEAP1 mutation status.Cancer treatment and research communications2026name in abstract: adagrasib
PMID 42077604Emerging precision therapeutics for pancreatic ductal adenocarcinoma: KRAS and beyond.Therapeutic advances in medical oncology2026name in abstract: adagrasib
PMID 42098425Evaluating the efficacy of G12C inhibitors in conjunction with Gamma Knife radiosurgery for KRAS-mutant non-small cell lung cancer brain metastases.Journal of neuro-oncology2026name in abstract: adagrasib
PMID 42114191Romidepsin inhibits NRF2 and enhances the efficacy of adagrasib by inducing autophagic cell death in KRAS-mutant tumor cells.Bioorganic chemistry2026name in title: adagrasib
PMID 42114275KRAS G12C-mutant non-small cell lung cancer: A practical guide for clinicians.Cancer treatment reviews2026name in abstract: adagrasib
PMID 42122163Discovery of Structurally Distinct Covalent KRAS G12C Inhibitor Scaffolds Through Large-Scale In Silico Screening and Experimental Validation.Cancers2026name in abstract: adagrasib
PMID 42170277Pre-clinical efficacy of trastuzumab deruxtecan plus sotorasib in KRASG12C -mutant non-small cell lung cancer and exploratory HER2 profiling in human tumors.Translational lung cancer research2026name in abstract: adagrasib
PMID 42234744Monoclonal antibodies targeting PCDH7 inhibit tumor growth and enhance immune responses in KRAS-mutant non-small cell lung cancer.Science advances2026name in abstract: adagrasib
PMID 42244998Development and in vivo evaluation of 18F-labeled PET tracers covalently targeting KRAS-G12C for noninvasive cancer diagnosis and therapy monitoring.Theranostics2026name in abstract: adagrasib
PMID 42254833Combining the KRASG12C inhibitor adagrasib with anti-PD-1 immunotherapy improves overall survival and prevents recurrence in preclinical models of brain metastasis.Neuro-oncology advances2026name in title: adagrasib
PMID 42258763KRAS Inhibitor-Induced Cancer Cell Death Enhances Sensitivity to Immune-Mediated Bystander Killing of Drug-Resistant Subclones.Cancer research2026name in abstract: adagrasib
PMID 42279426Pan-RAS Inhibitors: Expanding Therapeutic Potential and Evading Resistance.Cancers2026name in abstract: adagrasib
PMID 42282123Study of the blood-brain barrier-penetrating KRAS G12C inhibitor JMKX1899 in KRAS G12C-mutated NSCLC with brain metastases.Journal of the National Cancer Center2026name in abstract: MRTX849
PMID 42283833Drug repurposing in KRAS G12C-mutant NSCLC: a focus on resistance mechanisms and clinical strategies.Naunyn-Schmiedeberg's archives of pharmacology2026name in abstract: adagrasib
PMID 42290615Opioid toxicity from impaired oxycodone metabolism associated with adagrasib.Clinical toxicology (Philadelphia, Pa.)2026name in title: adagrasib
PMID 42294187Machine Learning-Driven Drug Repurposing for KRAS G12C and KRAS G12D Inhibition.ACS omega2026name in abstract: adagrasib
PMID 42325635Carborane Hydrophobic Tags Drive Selective Degradation of Endogenous KRASG12C via HSP70-Ubiquitin-Proteasome Pathway.ACS bio & med chem Au2026name in abstract: MRTX849
PMID 42336204Adaptive Feedback Signaling Through the FAK/SRC Pathway Promotes KRAS G12C Inhibitor Resistance.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer2026name in abstract: adagrasib
PMID 42386216Targeting KRAS for cancer therapy.British journal of pharmacology2026name in abstract: adagrasib
PMID 42398486In Silico identification of natural and synthetic inhibitors targeting KRAS mutants (G12D, G12V, and G12C) and wild-type in pancreatic cancer.Journal of molecular graphics & modelling2026name in abstract: adagrasib
PMID 42446418Expanding Addressable KRAS Mutations through the Structure- and Property-Based Design of Dual-State (GDP/GTP), Reversible Pan-KRAS Inhibitors.Journal of medicinal chemistry2026name in abstract: adagrasib
PMID 42448954KRAS-mediated CCDC6 degradation drives xCT upregulation and ferroptosis evasion.Apoptosis : an international journal on programmed cell death2026name in abstract: adagrasib
PMID 42450070Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies.International journal of molecular sciences2026name in abstract: adagrasib
PMID 42496289FDA-Approved Drugs Containing Amide Functionality in the Last Five Years (2021-2025): Pharmaceutical Use, Trends and Synthetic Approaches.Medicines (Basel, Switzerland)2026name in abstract: adagrasib
PMID 42511798KRAS G12C-Targeted Therapy in Non-Small Cell Lung Cancer: From Resistant Salvage to Potential First-Line Backbone.International journal of molecular sciences2026name in abstract: adagrasib
PMID 42513436Precision Therapeutics in Pancreatic Cancer: Emerging Targeted, Immune, and Antibody-Drug Conjugate Strategies Exemplified by Adagrasib, Dostarlimab, and Trastuzumab Deruxtecan.Journal of clinical medicine2026name in title: adagrasib
PMID 42514855RAS Inhibitors: Changing the Paradigm from the Undruggable.Pharmaceutics2026name in abstract: adagrasib
PMID 42551924[Therapeutic Strategies Targeting the KRAS G12C Mutation-Current Landscape and Future Directions].Gan to kagaku ryoho. Cancer & chemotherapy2026name in abstract: adagrasib
PMID 42551925[Development of Therapies Targeting Non-G12C KRAS Mutations (Focusing on G12D and Pan-RAS)].Gan to kagaku ryoho. Cancer & chemotherapy2026name in abstract: adagrasib
PMID 42557306M1C is a druggable target for NSCLC KRAS G12C mutant tumors resistant to KRAS inhibitors.Oncogene2026name in abstract: adagrasib
PMID 42571010The KRAS targeting revolution in metastatic pancreatic cancer: insights from the landmark RASolute-302 trial and emerging allele-specific strategies at ASCO 2026.Journal of hematology & oncology2026name in abstract: adagrasib
PMID 42593915Property-Biased Covalent DNA-Encoded Library Screening Enabled the Discovery of AM-8719, A Structurally Novel, CNS-Penetrant KRAS G12C Inhibitor.Journal of medicinal chemistry2026name in abstract: adagrasib
PMID 42611092KRAS G12C-mutated Metastatic Colorectal Cancer: Current Therapeutic Strategies and Future Directions.Journal of gastrointestinal cancer2026name in abstract: adagrasib
PMID 42622884KRAS-Targeted Therapies in NSCLC: Resistance, Combination Strategies, and Emerging Clinical Paradigms.Medical oncology (Northwood, London, England)2026name in abstract: adagrasib
PMID 42624145Patient-reported outcomes with adagrasib in KRYSTAL-12.Lancet (London, England)2026name in title: adagrasib
PMID 42688109Targeting KRASG12C in non-small cell lung cancer: evidence from randomized clinical trials and future therapeutic strategies.Frontiers in oncology2026name in abstract: adagrasib
PMID 42695382Clinicopathologically supported photodistributed hyperpigmentation with associated nail changes during adagrasib therapy.Clinical and experimental dermatology2026name in title: adagrasib
PMID 42699034Theoretical study of KRAS G12C secondary mutations influencing inhibitor resistance.Biophysics and physicobiology2026name in abstract: adagrasib
PMID 42707601KRAS mutations as architects of the tumor immune microenvironment: implications for combination therapies.Frontiers in oncology2026name in abstract: adagrasib
PMID 42720810Beyond KRASG12C: emerging therapeutic strategies, patent landscape, and clinical progress in targeting KRAS-mutant cancers.Medical oncology (Northwood, London, England)2026name in abstract: adagrasib
PMID 42749446Computational identification and characterization of high-risk human KRAS nsSNPs: Impacting structure, ligand binding, and cancer prognosis.Journal, genetic engineering & biotechnology2026name in abstract: adagrasib
PMID 42759542Targeting KRAS-Mutant Lung Cancers.Journal of the National Comprehensive Cancer Network : JNCCN2026name in abstract: adagrasib
PMID 42860233Blockade of mutant RAS oncogenic signaling: A 2026 update.Pharmacological research2026name in abstract: adagrasib
PMID 42870846Activity and specificity of KRAS variants-directed Revolution Medicines Company (RMC) compounds for pleural effusion-derived non-small cell lung cancer cell lines.Translational lung cancer research2026name in abstract: adagrasib
PMID 42890422Molecular Mechanisms and Therapeutic Advances in KRAS G12C-Mutant Non-Small Cell Lung Cancer: Toward Mechanism-Guided Longitudinal Management.Cancer innovation2026name in abstract: adagrasib
PMID 42945155Divarasib Bests 1st-Generation KRASG12C Inhibitors.Cancer discovery2026name in abstract: adagrasib
PMID 42967565Combination of canagliflozin and adagrasib as a novel targeted therapy for LKB1-KRASG12C co-mutated NSCLC.Cancer letters2026name in title: adagrasib
PMID 42975930Rapid target engagement of KRAS G12C tricomplex inhibitor RO3903 overcomes resistance and drives durable tumor regression.Proceedings of the National Academy of Sciences of the United States of America2026name in abstract: adagrasib
PMID 43001251From "undruggable" to tractable: Therapeutic advances targeting Kristen rat sarcoma viral homolog glycine to cysteine mutation at codon 12 (KRAS G12C)-mutant cancers and emerging resistance mechanisms.Cancer pathogenesis and therapy2026name in abstract: adagrasib
PMID 43023285Mechanisms of Resistance to KRAS G12C Inhibitors and the Rationale for Targeting the PI3K/AKT/mTOR Pathway in Advanced NSCLC.Mini reviews in medicinal chemistry2026name in abstract: adagrasib
PMID 37936461A New Dawn for Targeted Cancer Therapy: Small Molecule Covalent Binding Inhibitor Targeting K-Ras (G12C).Current medicinal chemistry2025name in abstract: adagrasib
PMID 38486394Structural insights into non-hotspot KRAS mutations and their potential as targets for effective cancer therapies.Journal of biomolecular structure & dynamics2025name in abstract: adagrasib
PMID 39404173Advances and Challenges in RAS Signaling Targeted Therapy in Leukemia.Molecular cancer therapeutics2025name in abstract: adagrasib
PMID 39506389KRAS inhibitors in drug resistance and potential for combination therapy.Tumori2025name in abstract: adagrasib
PMID 39522850KRAS mutations in advanced non-small cell lung cancer: From biology to novel therapeutic strategies.Critical reviews in oncology/hematology2025name in abstract: adagrasib
PMID 39587812Clinical and Physiologically Based Pharmacokinetic Model Evaluations of Adagrasib Drug-Drug Interactions.Clinical pharmacology and therapeutics2025name in title: adagrasib
PMID 39711431Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification.Molecular cancer therapeutics2025name in abstract: adagrasib
PMID 39725152WEE1 confers resistance to KRASG12C inhibitors in non-small cell lung cancer.Cancer letters2025name in abstract: adagrasib
PMID 39732595KRAS inhibitors: resistance drivers and combinatorial strategies.Trends in cancer2025name in abstract: adagrasib
PMID 39804166Impact of Co-mutations and Transcriptional Signatures in Non-Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 Trial.Clinical cancer research : an official journal of the American Association for Cancer Research2025name in title: adagrasib
PMID 39825361KEAP1 mutations as key crucial prognostic biomarkers for resistance to KRAS-G12C inhibitors.Journal of translational medicine2025name in abstract: MRTX849
PMID 39881149Comparative study of degree, neighborhood and reverse degree based indices for drugs used in lung cancer treatment through QSPR analysis.Scientific reports2025name in abstract: adagrasib
PMID 39894719Adagrasib-induced photodistributed hyperpigmentation: Two case reports and pathogenetic hypothesis.Therapie2025name in title: adagrasib
PMID 39914665Genomic landscape of clinically acquired resistance alterations in patients treated with KRASG12C inhibitors.Annals of oncology : official journal of the European Society for Medical Oncology2025name in abstract: adagrasib
PMID 39941797The Role of KRAS Mutations in Colorectal Cancer: Biological Insights, Clinical Implications, and Future Therapeutic Perspectives.Cancers2025name in abstract: adagrasib
PMID 40009739The Pharmacologic Inhibition of KRAS Mutants as a Treatment for Cancer: Therapeutic Principles and Clinical Results.Deutsches Arzteblatt international2025name in abstract: adagrasib
PMID 40023579In vitro metabolism of targeted covalent inhibitors and their thiol conjugates by gut microbiome from rats, mice, and humans.Drug metabolism and disposition: the biological fate of chemicals2025name in abstract: adagrasib
PMID 40052089Structural insights, regulation, and recent advances of RAS inhibitors in the MAPK signaling cascade: a medicinal chemistry perspective.RSC medicinal chemistry2025name in abstract: adagrasib
PMID 40082968ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic ductal adenocarcinoma.Molecular cancer2025name in abstract: adagrasib
PMID 40093982Immunotherapy in advanced, KRAS G12C-mutant non-small-cell lung cancer: current strategies and future directions.Therapeutic advances in medical oncology2025name in abstract: adagrasib
PMID 40109589Adagrasib plus cetuximab - a novel therapy in the KRAS G12C mutated colorectal cancer treatment.Annals of medicine and surgery (2012)2025name in title: adagrasib

NIH grants

ProjectTitleOrganisationPIYearsLinked by
K01CA313805Targeting a novel covalent RAS dimer in RASQ61 mutants-driven cancersUT SOUTHWESTERN MEDICAL CENTERZHOU, ZHIWEI2026–2026name in abstract: adagrasib
K22CA276357Targeted degradation of KRAS oncoproteins triggers antitumor immunity and abolishes lung tumorUNIVERSITY OF PITTSBURGH AT PITTSBURGHZHANG, HUA2024–2026name in abstract: MRTX849
R01CA279264Mechanisms of adaptation and resistance to emerging therapies for lung cancerSLOAN-KETTERING INST CAN RESEARCHLITO, PIRO2023–2026name in abstract: adagrasib
R01CA281295KRAS G12C: Kinetic and Redox Characterization of Covalent InhibitionUNIV OF NORTH CAROLINA CHAPEL HILLCAMPBELL, SHARON L2023–2026name in abstract: adagrasib
R01CA285926Targeting cytoplasmic SET oncoprotein by sphingolipid analog drugs for the induction of necroptosis to treat lung cancerMEDICAL UNIVERSITY OF SOUTH CAROLINAOGRETMEN, BESIM2024–2026name in abstract: adagrasib
R01CA296154Highly tumor-selective pan RAS inactivators for targeting oncogenic RAS-driven cancersUNIVERSITY OF PITTSBURGH AT PITTSBURGHLIU, SHIHUI2025–2026name in abstract: adagrasib
R01CA296978Targeting molecular mechanisms of the adeno-to-squamous transition in non-small cell lung cancer treatment adaptationNEW YORK UNIVERSITY SCHOOL OF MEDICINEYANAI, ITAI2025–2026name in abstract: adagrasib
R01CA311659Covalent Inhibitors of Ras Q61 Mutations in CancerUNIVERSITY OF CALIFORNIA, SAN FRANCISCOHUANG, BENJAMIN2026–2026name in abstract: adagrasib
R21CA296712Proximity-triggered, mutant-specific modification of K-Ras(G12C) with local polypharmaceutical releaseCOLD SPRING HARBOR LABORATORYMOSES, JOHN EDWARD2025–2026name in abstract: adagrasib
U54CA224083Research Project 2WASHINGTON UNIVERSITYLIM, KIAN-HUAT2023–2026name in abstract: adagrasib
R21CA297690Noncovalent interaction of mutant KRAS inhibitorsDUKE UNIVERSITYCHI, JEN-TSAN ASHLEY2025–2025name in abstract: adagrasib
R21CA302807Exploiting synthetic lethality to enhance KRAS inhibitor therapy of cancerNEW YORK UNIVERSITY SCHOOL OF MEDICINENEEL, BENJAMIN G.2025–2025name in abstract: adagrasib
R44AI177220Mitigation of Radiation Induced Gastrointestinal Syndrome.BCN BIOSCIENCES, LLCNORRIS, ANDREW JOHN2023–2025name in abstract: adagrasib
ZIABC011892Targeting RAS in Pediatric CancerDIVISION OF BASIC SCIENCES - NCIYOHE, MARIELLE2019–2025name in abstract: adagrasib
ZIASC006321Modulation of Therapeutic ResponseDIVISION OF CLINICAL SCIENCES - NCIMITCHELL, JAMES2024–2025name in abstract: adagrasib
F31CA261061Interrogating the role of mutant KRAS allelic imbalance and co-mutated genes in targeted therapy response of NSCLCWEILL MEDICAL COLL OF CORNELL UNIVDIAZ, BIANCA2021–2024name in abstract: MRTX849
R21CA282568Overcoming resistance to KRAS inhibitors through a fragment-based chemoproteomics approachH. LEE MOFFITT CANCER CTR & RES INSTHAURA, ERIC B.2023–2023name in abstract: adagrasib
ZIABC010440Protein Structure, Stability, and Amyloid FormationDIVISION OF BASIC SCIENCES - NCINUSSINOV, RUTH2022–2023name in abstract: adagrasib

Notes

KRAS G12C (OFF-state covalent). Mirati acquired by BMS Jan 2024. Approved (Krazati).

How to cite

adagrasib (AXP000024.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000024.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.